tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Stoke Therapeutics reports Q2 EPS (40c), consensus (54c)

Reports Q2 revenue $13.8M, consensus $5.2M. “This quarter was defined by strong execution that is driving momentum across our business,” said Ian F. Smith, CEO. “Our Phase 1/2 and open-label extension studies have provided a strong foundational understanding of zorevunersen and support the EMPEROR Phase 3 registrational study design. We continue to generate long-term data that are helping us appreciate the disease modifying potential of zorevunersen. At the same time, we see growing awareness of Dravet syndrome as a severe neurodevelopmental disease, which is bringing attention to our work and a high degree of interest in zorevunersen.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1